share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

Hong Kong Stock Exchange ·  May 27 21:49
Summary by Futu AI
药明生物技术有限公司於2024年5月27日完成一系列股份購回活動，並根據香港聯合交易所有限公司證券上市規則披露相關信息。該公司在2023年12月7日至2024年5月27日期間，透過香港聯合交易所進行了多次股份購回，總計購回股份數目達105,488,000股，佔已發行股份的2.483%。最後一次購回發生在2024年5月27日，當日購回2,520,000股，每股價格介於HKD 11.8至HKD 11.94之間，總付出金額為HKD 29,907,460。此外，公司亦根據股份期權計劃行使期權，但不包括董事行使的情況。药明生物確認已收取所有應得款項，並已履行所有上市先決條件，包括相關法律規定及文件存檔等。股份購回後，公司的結存股份總數為4,262,479,429股。
药明生物技术有限公司於2024年5月27日完成一系列股份購回活動，並根據香港聯合交易所有限公司證券上市規則披露相關信息。該公司在2023年12月7日至2024年5月27日期間，透過香港聯合交易所進行了多次股份購回，總計購回股份數目達105,488,000股，佔已發行股份的2.483%。最後一次購回發生在2024年5月27日，當日購回2,520,000股，每股價格介於HKD 11.8至HKD 11.94之間，總付出金額為HKD 29,907,460。此外，公司亦根據股份期權計劃行使期權，但不包括董事行使的情況。药明生物確認已收取所有應得款項，並已履行所有上市先決條件，包括相關法律規定及文件存檔等。股份購回後，公司的結存股份總數為4,262,479,429股。
Pharma Ming Biotechnology Limited completed a series of share repurchase activities on 27 May 2024 and disclosed information in accordance with the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited. The Company made multiple share repurchases through the Hong Kong Stock Exchange between 7 December 2023 and 27 May 2024 for a total repurchase of 105,488,000 shares, representing 2.483% of the issued shares. The last repurchase took place on 27 May 2024 and repurchased 2,520,000 shares at a price of HKD 11.8 to HKD 11.94 per share, with a total payout of HKD 29,907,460. In addition, the Company exercises options under the Share Option Scheme, but excluding those exercised by directors. Pharma Biologics confirms that it has received all monies due and that it has fulfilled all the pre-requisites for listing, including relevant legal requirements and archiving documents, etc. After the share repurchase, the total number of outstanding shares of the company is 4,262,479,429 shares.
Pharma Ming Biotechnology Limited completed a series of share repurchase activities on 27 May 2024 and disclosed information in accordance with the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited. The Company made multiple share repurchases through the Hong Kong Stock Exchange between 7 December 2023 and 27 May 2024 for a total repurchase of 105,488,000 shares, representing 2.483% of the issued shares. The last repurchase took place on 27 May 2024 and repurchased 2,520,000 shares at a price of HKD 11.8 to HKD 11.94 per share, with a total payout of HKD 29,907,460. In addition, the Company exercises options under the Share Option Scheme, but excluding those exercised by directors. Pharma Biologics confirms that it has received all monies due and that it has fulfilled all the pre-requisites for listing, including relevant legal requirements and archiving documents, etc. After the share repurchase, the total number of outstanding shares of the company is 4,262,479,429 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.